Aktienanalyse zu RadNet Inc (RDNT)RDNTRadNet Inc

RadNet, Inc. is a national provider of fixed-site diagnostic imaging services in the United States. The Company has a network over of 435 owned and/or operated outpatient imaging centers. Its Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis & treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Its Digital Health segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. It provides radiology information technology and artificial intelligence (AI) solutions marketed under the DeepHealth brand and teleradiology professional services. It is also a provider of AI-powered breast health solutions. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

RadNet Inc is a good buy right now due to its recent strong revenue growth of 25% year-over-year, reaching $622.7 million in Q2 2026, and an improved adjusted EBITDA margin of 16.1%. Despite some profitability challenges, the stock's current price of $70.34 is below the analyst price target of $94, indicating significant upside potential. However, a risk to consider is the forward P/E ratio of 36.63, which suggests high valuation expectations that may not be met if profit growth does not accelerate.

2 analysts cover RDNT: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 90.17.